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Cardiovascular disease is the leading cause of death inwomen in theUnited States. Aging is a primary risk factor for the development
of cardiovascular disease as well as cardiovascular-related morbidity and mortality. Aging is a universal process that all humans
undergo; however, research in aging is limited by cost and time constraints. Therefore, most research in aging has been done in
primates and rodents; however it is unknown how well the effects of aging in rat models translate into humans. To compound the
complication of aging gender has also been indicated as a risk factor for various cardiovascular diseases. This review addresses
the systemic pathophysiology of the cardiovascular system associated with aging and gender for aging research with regard to the
applicability of rat derived data for translational application to human aging.
1. Introduction
In 2005, cardiovascular disease (CVD) was the underlying
cause of death in 864,480 of the approximately 2.5 million
total deaths in the United States [1, 2]. CVD is the leading
cause of death and the most costly disease in America and
is expected to increase in costs to $1.48 trillion by 2030 [3].
Although the focus has been to reduce themodifiable risk fac-
tors for cardiovascular disease (such as lipid levels, diabetes,
and sedentary lifestyle), the unmodifiable risk factor, aging,
is a major risk factor for coronary disease, hypertension,
congestive heart failure, and stroke [4]. The number of the
aged in theUnited States is projected to increase bymore than
20% by the year 2030. This growth in the elderly population
is expected to significantly test our already overloaded health
care system.
Although years of research have been conducted in
regard to aging, we are still a long way from understanding
the intricacies of age-related changes in human physiology,
in particular the cardiovascular system. Whether aging in
animal models mimics many of the cardiovascular changes
seen in humans is not well understood. In addition, the
process of delineating the effect gender has on aging provides
yet another variable to be considered.
2. Discussion
2.1. Aging and Cardiovascular Disease. Aging is believed by
some to be a progressive disorder that decreases an organism’s
ability to maintain reproductive capacity and “normostasis”
[5]. Indeed a strong correlation exists between aging and
higher incidence of several diseases including dementia,
Parkinson’s disease, diabetes, cancer, and Alzheimer’s disease
[5]. In the cardiovascular system, aging is positively corre-
lated with an increasing risk of cardiac problems including
arrhythmias and is a major independent risk factor for
cardiovascular-related morbidity and mortality [6]. Indeed,
more than 70% of males and females over 75 years of
age present some clinically evident cardiovascular disease
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(CVD) [7]. In addition to age, CVD risk also appears to
vary with sex. CVD is the number one killer of women in
Western nations [8]. Among women, more than 200,000
of the 454,613 total CVD deaths occurred in those above
85 years of age [2]. Although cardiovascular risk increases
with age in both sexes, the increase in age-associated risk
appears to be sharper in women [9]. Why CVD risk may
differ between men and women is not well understood but
may be related to differences in age-associated cardiovascular
function [10]. Whereas congestive heart failure in men is
oftentimes due to systolic insufficiencies, congestive heart
failure in women is often related to diastolic dysfunction
[10, 11]. The incidences of ischemia, cardiac failure, and
cardiac rupture in addition to ventricular remodeling have
also been shown to differ between genders with aging and
often lead to worse outcomes in women [12–15]. Recent data
suggests that premenopausal women have a decreased risk
of CVD compared to men of comparable age [16, 17]. This
cardioprotective benefit appears to be lost over time as the
risk of developing cardiovascular disease in postmenopausal
women increases to a rate that is similar to that observed
in men [18]. The reason(s) for this increase in CVD risk
following menopause is currently unclear; however, it is well
known that early menopause is associated with an increased
risk for coronary heart disease and cardiovascular disease
death [19–21]. This finding is thought to be related, at least in
part, to diminished estrogen exposure [22]. Consistent with
this notion, each year of increasing age at natural menopause
has been found to be associated with a 2% increase in total
cardiovascular mortality [22, 23]. Whether differences in
estrogen alone or changes in estrogen alongwith other factors
can fully explain the sex related differences in age-related
cardiovascular function is unknown and requires further
investigation.
2.2. Aging Female Rat Models. Human aging research is
limited due to cost, differences in lifestyle/history, and more
importantly the time required for data collection as well as
analysis of that particular system. Importantly, there are a
number of different animalmodels that can be used to acquire
information on how aging affects the female cardiovascular
system. The most applicable aging female animals studied
include primates. Primates are the closest in regard to female
human aging due to the fact that they are the only species
to undergo menstrual sloughing of the endometrial lining.
Nonetheless, it is important to note that female primates do
not experiencemenopause [25]. In addition, primate research
is oftentimes ethically difficult to perform and costly.
Rats are widely used in aging research as they exhibit a
relatively short lifespan and are genetically quite homoge-
nous. Among the various strains of rats, the Wistar, F344,
and F344/Brown Norway are the most common used aging
female rat models [26–30]. Although rats do not experience
menses, they do experience estrus cycling and ovarian aging.
Table 1 presents the stages of ovarian aging in female rats.
Reproductivematurity is reached at fivemonthswhen there is
an estrous cycle that lasts four to five days. Aging rats exhibit
periods of persistent estrous cycle which consists of elevated
and constant levels of estradiol, low levels of progesterone,
and lack of luteinizing hormone (LH) surges, in addition to
ovulation [24, 31, 32]. Ovarian decline occurs between six
and eighteen months depending on the rodent strain and
is characterized by low levels of estradiol and progesterone,
with little or no developing follicles and increased prolactin
secretion [24, 31, 32].
Comparisons between aging research in female rats
models and humans can be complicated due to the differences
in the mechanisms of ovarian/hormone aging in human
females and its potential impact on cardiovascular disease.
Though not fully understood, it is thought that the loss of
the hormones estrogen and progesterone in aging human
females is due to the decrease in the ovarian follicular reserve
[33]. Conversely, aging female rats experience a persistent
estrous cycle due to chronic anovulation which consist of
pseudopregnant/disestrus estrogen levels as well as high
progesterone levels from increased ovulation and the corpora
lutea [33]. Therefore, reproductive senescence in female rats
consists of alterations in the hypothalamic-pituitary axis
while reproductive senescence in human females is classified
as ovarian follicle depletion [33]. Due to these reasons and
others, caution should be exercised in extrapolating the
results from rodent studies to humans. Although estrogen
secretion by the ovary promotes hypothalamic changes, the
chronic administration of estrogen can damage neurons
in the arcuate nucleus and medial basal hypothalamus.
Therefore, it can be important to remember that the surgical
removal of the ovaries can lead to neurological changes that
may affect other organs during the aging process.
2.3. Ovariotoxicity and Ovariectomy on the Aging Cardiovas-
cular System. The pharmacological acceleration of ovarian
aging using 4-vinylcyclohexene diepoxide (VCD) (accel-
erated ovarian failure (AOF) [34] model) or ovariectomy
(OVX) procedures are often performed due to the lack of
natural menopause in rat research models because they are
believed to better mimic the hormone milieu seen in aging
human females. VCD has been shown to target the plasma
membrane of the primordial and primary follicles through
direct inhibition of autophosphorylation of the oocyte-
associated receptor, Kit [35]. Kit acts as an antiapoptotic
factor in primordial follicular survival [36, 37]. Although an
effective model of chemical ovotoxicity limited research has
been performed using female rat models [38–41] and to date
no published data exist regardingVCDand rat cardiovascular
aging. VCD in juvenile (1 month) and adult (3 months)
Sprague-Dawley rats depleted follicles but had no effect on
the duration or onset of persistent estrus. However, FSH
levels were significantly high in VCD treated animals with
no change in cyclicity or serum levels of 17𝛽-estradiol [38].
The absence of a human based clinical menopausal hormone
profile in the AOF model brings into question the ability to
apply data derived from this model for translational rele-
vant treatment of cardiovascular human based menopausal
pathologies.
An ovariectomy is the removal of the ovaries which
induces a surgical menopause characterized by the cessation
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Table 1: Stages of ovarian aging in a female rat as described by Lu et al. (1979) [24].
Age (months) Stages of ovarian aging in female rats
5 months
Reproductive maturity
(i) Estrous cycle (4-5 days)
(ii) Elevated and constant levels of estradiol
(iii) Low levels of progesterone
(iv) Lack of hormone surges and ovulation
6–8 months
Ovarian decline
(i) Decreased levels of estradiol and progesterone
(ii) Little or no follicles
10–12 months Irregularity of estrous cycles
19 months
Constant estrous cycle
(i) Low to medium levels of serum estradiol, estrone, testosterone, androstenedione, and progesterone
(ii) Very low levels of 20𝛼-hydroxyprogesterone
(iii) No preovulatory release of gonadotropin and prolactin
(iv) Increased levels of FSH
24 months
Prolactin
(i) Increased levels of prolactin (abolished by ovariectomy)
(ii) Retained ability to develop follicles and corpora
(iii) Retained ability to secrete steroid hormones
of estrogen and progesterone, as well as reduced production
of testosterone. Surgical menopause leads to more severe and
sudden symptoms compared to that observed during the nat-
ural human menopause where ovaries produce lower levels
of hormones over time. Like that seen in menopausal human
females, ovariectomy in rats also increases cardiovascular risk
[42, 43].
Studies have found that the majority of human females
who undergo natural menopause exhibit different age-
associated cardiovascular alterations than those who under-
went ovariectomy-inducedmenopause [44]. Elective bilateral
removal of the ovaries at a young age is associated with
an increased risk for cardiovascular disease and prema-
ture death [43]. In addition to declines in well-being and
sexual function, it is thought that elective oophorectomies
are also associated with elevated risk of cognitive impair-
ment, dementia, and Parkinsonism [43]. It is not known
whether the increased risk to cardiovascular disease is due
to alterations in hormones or the hypothalamic-pituitary
axis [43]. As expected, bilateral oophorectomy is associated
with different hormonal alterations including changes in
estrogen production and reduced levels of progesterone and
testosterone, as well as increases in gonadotropins (LH and
follicle stimulating hormone (FSH)), compared to those that
occur in human females who experience natural menopause
[45, 46].
In rats, ovariectomy causes alterations to heart structure
and function which include increases in cardiac interstitial
space, cardiac fibrosis, heart weight, and left ventricular
weight [47]. Ovariectomy in rats has been shown to reduce
cardiac contractility [48]. Ovariectomized rats appear to
exhibit increased evidence of oxidative stress and cardiac
apoptosis [47–51]. In rats, cytokine expression (tumor necro-
sis factor-alpha (TNF-𝛼) and interleukin-1 beta (IL-1𝛽)) and
angiotensin converting enzyme (ACE) and angiotensin II
type 1 receptor gene expression also appear to be increased
following ovariectomy [48, 50]. When estradiol treatment
was given to ovariectomized rats, it prevented the reduction
of cardiac contractility as well as the increase in apoptosis
and cytokine expression [48, 51]. Research in other rats,
namely, aging female Dahl salt-sensitive rats, has shown that
female rats are more likely to develop hypertension after
ovariectomy [52]. The researchers postulated that estrogen
protects against the increased activity of the renin angiotensin
system. However, in human females, research has shown
that postmenopausal hypertension occurs approximately five
to 10 years after menopause, not immediately after starting
menopause. Therefore, other age-related causes must occur
independently of estrogen loss that promotes CVD in post-
menopausal human females, as is shown by the fact that
estrogen replacement therapy is not cardioprotective after
menopause [53, 54]. Interestingly, both natural and surgically
induced reproductive senescence rats exhibit increased FSH
as well as decreased levels of estradiol and inhibin (A/B) [55].
Surgically induced reproductive senescence in rats has also
been shown to alter dopamine receptor affinity in the heart
[55].
Alterations in cardiac structure and function are not the
only alterations found after ovariectomy. Compared to aged
controls, human females that underwent prophylactic bilat-
eral salpingo-oophorectomy exhibit increased total and low-
density lipoprotein cholesterol levels [56]. In light of the
fact that within human females natural menopause and
ovariectomy results altered hormonal profiles and cardiovas-
cular risk, the data suggest that age-associated cardiovascular
disease in human females may be associated with both time
dependent hormone deprivation and age-associated changes
in structure, function, and protein signaling. Of note is
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the fact that most studies have used ovariectomized female
rats at young ages (6–12 weeks old) to examine the effects of
hormone deprivation on the cardiovascular systemwhich can
lead to unreliable results given that the cardiovascular system
has not yet “aged” [57].
2.4. Cardiac Structure and Function in the Aging Female
Rat. The increased risk of CVD in human females may
be due to differences in the type or magnitude of age-
associated alterations in cardiac structure and function.
Olivetti and colleagues have demonstrated a small decrease
in human heart weight with aging in males but not females
[58]. Additionally, no significant change was noted with
myocardium, left ventricular, or right ventricular free wall
weight in the aging human female heart with no underlying
cardiovascular pathology nor were age associated changes
detected in proportion, shapes, size, or number of mononu-
cleated and binucleated cardiac myocytes [58]. Given this
information, it appears that natural aging in human females
is not associated with cardiac remodeling during or after
menopause in the absence of preexisting pathologies or
loading abnormalities [58]. Similar conclusions were reached
from echocardiographic studies [59]. Although a limited
number of studies have looked at how cardiac structure
and function change with age in female rats, very few have
directly investigated how sexmay affect cardiac structure and
function. Go demonstrated that cardiovascular aging in male
and female rats demonstrated significant gender differences
in LV size and function [60].
Boluyt and colleagues investigated how aging may affect
cardiac structure and function in female F344 rats using
echocardiography [61]. Aging female rat cardiac structural
changes included a dilatation of the left ventricle between
13 and 22 months of age. This dilatation was characterized
by increases in posterior and septal wall thickness during
diastole at 22 and 30 months of age [61]. Aging in the female
F344 was also associated with increases in collagen content
and collagen cross-linking [62]. In addition, Boluyt and
colleagues demonstrated mild systolic dysfunction (decline
in left ventricle ejection fraction, fractional shortening, and
velocity of circumferential fiber shortening) in female 22-
month-old animals when compared to young adults and that
these changes preceded the development of mild diastolic
dysfunction [61, 63].These authors suggested that thismodest
decline in systolic function was due, at least in part, to a
shift in the amount of alpha and beta myosin heavy chains
[61, 62], similar to what is seen in the human failing heart
[64]. Additional work, perhaps using other rat models, is
needed in order to truly distinguish if these alterations are
due to increasing age or if they are simply specific to the F344
strain.
Fannin and colleagues found that increased age in the
female F344xBN was associated with increases in oxidative
stress and damage [65]. Age-related changes in cardiac struc-
ture were also found, such as increase in heart to body weight
ratio, cardiomyocyte cross-sectional area, posterior wall
thickening, and left ventricle chamber dilatation. Further,
increased age was also associated with diastolic dysfunction,
alterations in heart rhythm intervals, and alternations in
connexin 43 expression [65]. The presence of age-associated
cardiac structural changes in the F344 and F344xBN animal
models calls into question the use of these strains for
translational data, in light of the absence of age-associated
change in human females reported by Olivetti et al. [58].
Additionally, the menstrual cycle induced hormonal changes
have been shown to cause cardiac functional fluctuations
[66].This fact could indicate that the time at which functional
measurements are taken may impact the results and must
be a consideration in comparing all female derived cardiac
functional data.
2.5. Cardiac Arrhythmias with Aging. Aging is considered a
risk factor for ventricular arrhythmia [67, 68]. In addition,
aging is also associated with an increase in the percentage
of incidence of atrial fibrillation [60, 69]. In male rats, age-
associated increases in cardiac fibrosis as well as the changes
in gap junctionmorphology have been hypothesized to cause
changes in cardiac conduction in addition to the incidence
of arrhythmias and death [68, 70]. As humans age, there is
an increase in the EKG abnormalities which are associated
with increased mortality [71]. Men tend to experience more
atrial fibrillation, early repolarizations, Brugada syndromes,
and sudden cardiac death than women, while women are
more likely to be at risk to develop long QT syndrome-
based arrhythmias as well as bradycardia-induced torsades
de pointes [72]. Although sex related differences in cardiac
electrocardiogram parameters have been observed, electro-
cardiogram abnormalities seem to vary between studies. In
men, there is an increase in QRS duration and sinus cycle
length while women tended to a have a higher maximum
heart rate [73, 74].
Electrocardiogram analysis in elderly men and women
has demonstrated large or intermediate Q waves, left axis
deviation, negative T-waves, and complete right bundle
branch block as well as atrial fibrillation/flutter [75]. In aging
men, the QRS complex has been found to be narrowed, while
agedmen andwomen have been shown to undergo a leftward
shift of the QRS axis [75]. Another work has suggested that
puberty in men is associated with a shortened QT interval
which is not present in women [76] and that aging in men
demonstrates an increase in PR intervals and a prolongation
of the QT interval [74]. Conversely, another research found
that aging did not appear to alter EKG tracings in either men
or women [74].
Similar alterations in electrocardiogram parameters have
also been found in aging rats. In male Wistar rats, the PR
and corrected QT intervals were found to increase with age
[70]. Alterations in aging electrocardiogram parameters have
been shown to be rat strain dependent and could only be
detected subsequently to heart failure as in male SHHF/Mcc-
cp rat strain at 19 months of age [77]. Gonadectomy appears
to decrease the number of arrhythmias in male but not
female rats [78]. Though not fully understood, these differ-
ences in gender associated gonadectomy induced arrhythmia
frequency have been attributed to higher heart rates in
male animals and longer QT intervals, as well as gender
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differences in ion channel expression [79]. Very few studies
have investigated electrocardiogram parameters in the aging
female rat. Fannin and colleagues found that the arrhythmias
were not significantly higher in older female F344xBN rats
when compared with younger rats; however, the study did
find that valvular dysfunction was increased in the older rats
when compared to the younger ones [65].
The exact mechanisms of the gender associated reduction
of arrhythmias in humans and the role estrogen may play are
not fully understood but two potential indirect mechanisms
have been proposed. One potential indirect mechanism may
be related to the ability of estradiol to reduce the incidence of
cardiac ischemia [80]. Other works have suggested that high
levels of estradiol in female andmale rats may directly reduce
arrhythmias, possibly by causing slowing of the inward
calcium current [80, 81]. Although multiple studies have
investigatedEKGchanges in aging rats, these parameters have
not been determined in theNIA approved aging F344xBN rat
model. However, according to the ICH-S7B, the use of rats
for the safety testing of drugs is not considered appropriate
due to differences in the ionic mechanisms of repolarization
[82]. Arrhythmia mechanisms [83], resting heart rate, Ca+
homeostasis [84], and action potential configuration [85] are
all important differences that limit the translational relevance
of rat generated cardiovascular data for human application.
2.6. Aging Related Changes in Cardiac Oxidative Stress and
ROS-Related Signaling. Aging in the male rat heart is asso-
ciated with the accumulation of oxidative damage to lipids
and proteins as well as decline in mitochondrial enzymes
[86]. In addition, an increasing number of mutations in
mitochondrial DNA (mtDNA) has been gradually observed
during aging [87]. The level of 8-OHDG mtDNA adducts
and deletions increase exponentially with age [87]. In human
muscle, liver, and brain tissue, complex IV andmitochondrial
oxidative phosphorylation enzyme activities decline with age.
This decline in function is correlated with the accumulation
of mtDNAmutations, including deletions, and base substitu-
tions [87]. Similarly, aged male rat hearts exhibit an increase
in superoxide, 4-hydroxynonenal (4-HNE), and nitrosative
stress levels which appear to be highly correlated to increases
in left ventricular thickness [88].The exact role that increased
levels of oxidative stress may play in the development and
progression of age-associated cardiovascular disease remains
to be determined.
Compared to that observed in females, the hearts of
aging male rats exhibited increases in protein carbonyla-
tion, advanced oxidation protein products, nitrotyrosine,
nonprotein thiol, reduced glutathione, and iron levels [89].
Although aging is associatedwith increases in oxidative stress
in both male and female rat hearts, female rat hearts exhib-
ited lower mitochondrial hydrogen peroxide production,
oxidative damage, and a greater mitochondria differentiation
compared to that seen in male animals [90]. It is thought
that higher mitochondrial differentiation is a metabolic
adaptation to increase energy efficiency as it is associated
with their lower mitochondrial free radical production and
oxidative damage [90]. In addition to differences with sex, it
is also likely that reactive oxygen species (ROS) levels vary
with animal strain as female Wistar and F344 rats exhibit
lower ROS production and indices of oxidative damage than
that seen in female Sprague-Dawley rats which may help to
explain their greater mean lifespan [91, 92].
The mitogen-activated protein kinase (MAPK) cascades
are evolutionary conserved serine/threonine protein kinases
that regulate several important cellular functions including
proliferation, differentiation, development, cell cycle, and
cell death [93]. The major MAPK signaling pathways are
the extracellular signal-regulated protein kinase cascade
(p44/42), c-Jun amino-terminal kinase/stress-activated pro-
tein kinase cascade (JNK/SAPK), and the p38 cascade. Stim-
uli that include stress or injury typically activate the JNK and
p38 MAPK kinases, while the p44/42 MAPKs are stimulated
by mitogenic and growth factors [94, 95]. MAPK signaling is
involved in many of the age-associated physiological changes
(hypertrophy, oxidative stress, and apoptosis) as well as other
cardiac pathologies. Works investigating MAPK signaling in
aging human hearts have demonstrated reduced p38 MAPK
activity/signaling in heart failure and impaired activation of
MAPK target genes following increase in oxidative stress [96–
98].
It is well recognized that increases in cellular stress cause
the upregulation of the heat shock protein (Hsp) [99]. Hsps
range in size from 10 to 150 kDa and function to prevent
protein aggregation and assist in ensuring proper protein
folding, as well as helping to mediate the translocation of
damaged proteins [100]. Hsps are also involved in cardiac
hypertrophy, in response to vascular wall injury, ischemic
preconditioning, and aging [101]. During aging, there is an
accumulation of damaged or misfolded proteins which may
cause a burden on maintaining proteostasis [102–104]. An
important function of heat shock proteins is to protect against
age-related protein misfolding [103–105]. In aged male F344
rats (24 months), it appears that aging decreases Hsp70
upregulation following chronic exercise and heat stress [106–
108].
Similar to theMAPKproteins, the nuclear factor-𝜅B (NF-
𝜅B) pathway is thought to play a role in cardiac remodeling,
apoptosis, acute ischemia and reperfusion, and unstable
angina, as well as heart failure in both humans and rodents
[109–112]. The NF-𝜅B family consists of RelA (p65), c-Rel
(Rel), RelB, NF-𝜅B1 (p50), and NF-𝜅B 2 (p52). Figure 1
presents the NF-𝜅B signaling pathway. In the cytoplasm, the
p50 and p65 are found as an inactive heterodimer due to
the binding of the I𝜅B kinase inhibitory proteins (IKK𝛼 and
IKK𝛽). Cellular stimuli known to activate theNF-𝜅B pathway
include ROS, TNF-𝛼, IL-1𝛽, and bacterial lipopolysaccha-
rides [113]. It has been shown that the I𝜅Bs must first
become phosphorylated and degraded before p50/p65 acti-
vation can occur [113]. The p50/p65 when phosphorylated
(activated) then translocates into the nucleus to induce the
transcription of chemokines (IL-8, MCP-1), cytokines (TNF-
𝛼, IL-1, IL-2, IL-6), adhesion molecules (ICAM-1, VCAM-
1, E-selectin), acute phase proteins, antimicrobial peptides,
secondary inflammatory enzymes (COX-2, iNOS, PLA2,
MnSOD), and antiapoptotic factors [114]. Upon termination
of the NF-𝜅B stimuli, p50/p65 binds to new I𝜅Bs and

























Figure 1: The NF-𝜅B signaling pathway (see text for details).
the complex is translocated back to the cytoplasm. It is
thought that the MAPK pathway works in concert with the
NF-𝜅B pathway to increase transcription of inflammatory
genes [114]. Meldrum et al. extensively review the role of sex
hormones in intracellular signaling mechanisms within the
myocardial inflammation [66].
2.7. Activation of ROS-Related Signaling in the Female Aging
Heart. Although the effects of estrogen on MAPK signaling
have been studied in several pathological processes, for
example, breast cancer, migraines, and polycystic ovarian
syndrome, little is known regarding how this molecule affects
MAPK signaling in the heart. It is thought that differences
in MAPK activation between male and females may be
regulated, at least in part, by the influence of estrogen [66,
115, 116]. Estrogen has been shown to stimulate the activation
of p44/42MAPK and JNKMAPK in different model systems
including cardiomyocytes, mammary cancer cells, pituitary
tumor cells, tissue slices of the hippocampus, and endometri-
otic stromal cells [117–119]. Inmales as well as ovariectomized
females MAPK signaling is decreased after acute ischemia
[115, 116]. In a model of cardiac pressure overload, estradiol
treatment appeared to exhibit antihypertrophic effects by
increasing the expression of atrial natriuretic peptide (ANP)
and inhibiting p38-MAPK activation [120].
In addition to the regulation of MAPK proteins, there is
evidence to suggest that gender also has an effect on the Hsp
response. In hearts that were not exposed to increased cellular
stress, male hearts have half as much Hsp72 expression
compared to that observed in the female heart. Conversely,
ovariectomy was found to reduce Hsp72 levels in female
hearts [121]. Estradiol treatment has also been found to
increase Hsp27, Hsp70, Hsp72, and Hsp90 expression in the
heart [122–124]. To our knowledge, no studies have looked at
Hsp27, Hsp70, and Hsp90 in the aging female heart.
Aging female and male hearts have shown increased
apoptosis and inflammation, as well as age-associated gender
differences in NF-𝜅B signaling [125]. To our knowledge,
only a few studies have investigated the changes in NF-
𝜅B expression and activity in the aging female rat heart.
However, it has been reported that estradiol can decrease NF-
𝜅B binding activity [66].
2.8. Aging Heart Apoptosis. Apoptosis or programmed cell
death is a highly conserved and regulated cell response
to inhibit the abnormal proliferation of cells [126]. Car-
diomyocytes are not capable of self-regeneration and are
terminally differentiated but can undergo apoptosis, necrosis,
or autophagy when unduly stressed [127]. Apoptosis is
increased inmany cardiovascular diseases such as dilated and
ischemic cardiomyopathy, hypertrophic heart disease, and
arrhythmias [126, 128, 129]. In rats, increased age has been
shown to cause apoptotic susceptibility in the heart following
oxidative injury [130, 131]. Aging in the male F344xBN heart
is characterized by increases in the amount of cytochrome
C, AIF, Bax, rate of permeability transition pore opening,
and fragmented DNA [132]. The age-associated increase in
apoptosis appears to be due not only to the activation of
proapoptotic molecules but also to decreases in antiapoptotic
NF-𝜅B, Bcl-xL, and Grx1 signaling [130]. Another work
has demonstrated that the aging male F344xBN rat heart
is characterized by increases in TdT-mediated dUTP nick
end labeling- (TUNEL-) positive nuclei, caspase-3 activation,
caspase-dependent cleavage of alpha-fodrin, and diminished
phosphorylation of protein kinase B/Akt (Thr308) [133]. The
increase of apoptosis in the aging male F344xBN was highly
correlated to age-associated increases in oxidative-nitrosative
stress. Though not demonstrating cause and effect, these
results suggest that increased cellular ROS and cardiomyocyte
apoptosis may play a role in age-related cardiac remodeling.
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The incidence of cells undergoing apoptosis in the heart
has been shown to differ with sex in humans and rats.
In humans, a higher number of TUNEL positive myocytes
are seen in young males compared to females [58, 134]. In
humans, aging appears to increase cardiac apoptosis in male
but not female [58]; however, there was no gender difference
in apoptosis in male and female F344 rat [92, 135]. These
results suggest differences in apoptosis regulation between
species.
2.9. Effects of Aging on Aorta Structure and Function. Car-
diovascular disease affects not only the heart but the vas-
culature of the cardiovascular system. Structural changes
found in the aging vasculature include an enlarged lumen,
media-intimal thickening, irregularly shaped endothelial
cells, migration and proliferation of vascular smooth muscle
cells, increased deposition of extracellular matrix, increased
expression of adhesion molecules, and alterations in the
expression of metalloproteinases as well as cytokines [4, 136–
138]. Functional changes with age in the vasculature con-
sist of impaired distensibility, increased stiffness, increased
endothelial permeability, attenuation of 𝛽 2-adrenoceptor
vasodilator response to agonists, and diminished response
to adrenergic receptor stimulation [4, 139]. Like humans,
rats also appear to exhibit several age-associated changes in
vascular structure and function including changes in intimal
thickening, elevations in inflammation-associated molecule
expression, and increased evidence of oxidative stress [4, 140].
Similar to that seen in other parts of the cardiovascular
system, differences in aortic structure and function between
genders have also been observed in the aging human and
animals. In males, aortic wall and intimal-medial thickness
are greater during aging than that observed in women;
however, stiffness was not different betweenmen and women
[141]. Similarly, there were no differences in distensibility in
the aging aorta betweenmen and women [142]. Although the
human aging aorta did not show increases in aortic stiffness,
it has been documented that the increased vascular stiffness
with aging is more prominent in male than female animal
models [143, 144]. This may be due in part, to the lower
total peripheral resistance and higher cardiac output seen in
women compared to men of similar arterial pressure and age
[58].
Abnormal proliferation and migration of vascular
smooth muscle cells (VSMCs) play important roles in the
pathophysiology of atherosclerotic diseases [145]. Previous
studies have shown that VSMCs isolated from old animals
replicate more actively than those obtained from young
animals [145, 146]. Similarly, aging has been shown to be
associated with an increased proliferative response of VSMCs
after balloon angioplasty [147].
2.10. Effects of Aging on Aortic Endothelial Cell Function.
Endothelial dysfunction is considered to be a common and
early feature of vascular disease and impaired endothelium-
dependent relaxation has been demonstrated in several rat
models of hypertension, experimental diabetes, atheroscle-
rosis, and high salt diet, as well as aging [148]. The factors
regulating endothelial dysfunction are likely complex and
may vary between models and with aging. Nitric oxide (NO)
is a vasodilator that is produced by endothelial nitric oxide
synthase (eNOS) that plays a crucial role in blood pressure
regulation. NO production is stimulated by shear stress,
cyclic strain, acetylcholine, vascular endothelial growth fac-
tor, bradykinin, estrogen, sphingosine-1 phosphate (S-1P),
hydrogen peroxide, and angiotensin II [149]. It is thought
that eNOS activity is regulated by eNOS phosphorylation at
Serine 1177, Serine 635, and Serine 617 by phosphatidylinositol
3-kinase (PI3K)/Akt, adenosine monophosphate-activated
protein kinase (AMPK), and cyclic AMP-dependent protein
kinase signaling [149, 150]. Given its important role in regu-
lating vascular function, it is not surprising that abnormalities
in vascular NO production are thought to contribute to
the pathogenesis of atherosclerosis and hypertension [151,
152]. Advanced age has been found to be associated with
impaired endothelial NO synthesis and endothelial dysfunc-
tion [153, 154]. The mechanisms responsible [155] for age-
associated alterations in NO synthesis are not fully known
but may include changes in activity or expression of eNOS,
increased breakdown of NO due to oxidative stress/oxidative
injury, changes in antioxidant defense systems, and decreased
availability of eNOS substrate, L-arginine [155], although the
activity of eNOS is generally thought to be diminished with
aging [156] in the aorta. In addition to changes in eNOS activ-
ity, decreased NO availability during aging can also be caused
by oxidative stress [154] and alterations in eNOS structure
[155, 156].The regulation of eNOS function during agingmay
also differ with sex. Although estrogen (17-𝛽 estradiol) has
been shown to activate eNOS [157], estrogen studies in rats
have shown no effect [158] or increased eNOS expression
following estrogen treatment [159]. Conversely, in humans,
estrogen replacement appears to be largely ineffective as a
means of decreasing CVD risk [159, 160].
2.11. Sex Related Differences in Aortic Vascular Smooth Mus-
cle Cells with Aging. In women, the incidence of vascular
dysfunction is thought to be related, at least in part, to the
cessation of ovarian hormone production [161]. In vascular
smooth muscle cells from young female Wistar Kyoto rats,
estrogen inhibited VSMC proliferation following stimulation
with fetal calf serum [162]. This effect was thought to be
mediated by E2 receptors [162]. Similar decreases in VSMC
proliferation with estrogen treatment following cell stimula-
tion by growth factors or mechanical stress have also been
noted [161, 163]. Like estrogen, progesterone is also thought
to inhibit the proliferation of aortic VSMC, most likely via
its ability to inhibit DNA synthesis [164]. Nonetheless, it
should be noted that the effects of estrogen in vivo are likely
more complex than those seen in cell culture. For example,
in aortas from diabetic female rats, estrogen failed to reverse
the impaired basal release of nitric oxide and the abnormal
relaxation to histamine [165].
2.12. Aging Aorta Signaling. The MAPK signaling pathways
function to regulate many processes in the aorta including
VSMC proliferation, contraction, migration, differentiation,
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and cell survival [166–168]. Aging has also been shown to
increase the activation (phosphorylation) of p44/42 and JNK
MAPKs in the aorta [169] while another work has shown that
aging affects the ability of the aged aorta to activate p38 and
JNK MAPK signaling following mechanical loading [170].
In aged animals the activation of p44/42 MAPK in vascular
smooth muscle was increased compared to young animals
[145, 171].
Similar to that observed for the heart, age-associated
changes in the expression/activity of NF-𝜅B were found in
the vascular smooth muscle cells of the aorta. Aging has
been found to increase the sensitivity of NF-𝜅B to glucose
in aortic VSCM cells [172]. Another research has shown
that VSCM proliferation and NF-𝜅B activation stimulated by
interleukin-1𝛽 were increased more in aged female rats than
young female rats [173]. In premenopausal women, receiving
hormone treatment appeared to reduce NF-𝜅B activation
[174] suggesting that estradiol reducesNF-𝜅B activation.How
estrogen may inhibit NF-𝜅B activity is currently unclear but
may be related to increased I𝜅B levels or decreased levels of
circulating TNF-𝛼 [174].
3. Conclusion
In summary, the loss of ovarian function during aging may
influence cardiovascular structure and function. However,
the fact that human females do not display cardiac hypertro-
phy or myocyte loss in the absence of loading abnormalities
with aging may suggest the presence of estrogen prior to
menopause acts to attenuate the cardiac response to pre-
existing underlying pathologies. Due to the complexities of
the aging process, more studies are needed to distinguish
whether observed differences are due to aging alone, hor-
mone deprivation, or a combination of both. In order to
overcome the difficulties found in aging human research
(ethics, cost, and long lifespan), rat models have been used to
provide great insight in investigating age-related changes in
cardiovascular structure and function. However, additional
research examining how aging may affect cardiac structure
and function in rats is needed to determine whether the
alterations seen in rats mimic the changes seen in humans.
Because of the systemic nature of reproductive senescence,
the use of surgical practices to induce “pseudomenopause”
or ovariotoxicity may be incomplete in the overall approach
to female aging and cardiovascular changes. The global
changes in the body with age may play a cumulative role in
combinationwith the hormonal changes seen in reproductive
senescence. Aging-associated increases in oxidative stress can
lead to alterations in the cardiac cell signaling whichmay lead
to deleterious changes in the heart. Because cardiac structure,
function, signaling, and hormonal response appear to differ
between male and female rats and humans with aging, care
must be taken in evaluating current literature with regard to
specific finding and gender. Studies investigating the details
of cardiac signaling with gender and aging are likely to lead
to a better understanding of the mechanisms responsible
for cardiovascular diseases in both male and females. These
findings may prove critical in the application of current
prophylactic practices and pharmaceutical interventions in
patient outcomes.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
K. M. Rice and J. C. Fannin contributed equally to the study.
Acknowledgment
This work was supported in part by DOE Grant (DE-PS02-
09ER-01 to E. R. Blough).
References
[1] J. Johannes and C. N. Bairey Merz, “Is cardiovascular disease
in women inevitable?: preparing for menopause and beyond,”
Cardiology in Review, vol. 19, no. 2, pp. 76–80, 2011.
[2] A. Yazdanyar andA. B.Newman, “The burden of cardiovascular
disease in the elderly: morbidity, mortality, and costs,”Clinics in
Geriatric Medicine, vol. 25, no. 4, pp. 563–577, 2009.
[3] A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and
stroke statistics—2013 update: a report from the American
Heart Association,”Circulation, vol. 127, no. 1, pp. e6–e245, 2013.
[4] E. G. Lakatta, “Arterial and cardiac aging: major shareholders
in cardiovascular disease enterprises: part III: cellular and
molecular clues to heart and arterial aging,”Circulation, vol. 107,
no. 3, pp. 490–497, 2003.
[5] A. Anna, D. R. Riordon, and K. Boheler, “Molecular mecha-
nisms of cardiomyocyte aging,” Clinical Science, vol. 121, no. 8,
pp. 315–329, 2011.
[6] F. Hatch, M. K. Lancaster, and S. A. Jones, “Aging is a primary
risk factor for cardiac arrhythmias: disruption of intracellular
Ca2+ regulation as a key suspect,” Expert Review of Cardiovas-
cular Therapy, vol. 9, no. 8, pp. 1059–1067, 2011.
[7] A. Karavidas, G. Lazaros, D. Tsiachris, and V. Pyrgakis, “Aging
and the cardiovascular system,” Hellenic Journal of Cardiology,
vol. 51, no. 5, pp. 421–427, 2010.
[8] W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and
stroke statistics—2008 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e146, 2008.
[9] L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T.
Manolio, and E. Barrett-Connor, “Cardiovascular disease in
women: a statement for healthcare professionals from the
American Heart Association. Writing Group.,” Circulation, vol.
96, no. 7, pp. 2468–2482, 1997.
[10] H. Okura, Y. Takada, A. Yamabe et al., “Age-and gender-spe-
cific changes in the left ventricular relaxation a doppler echocar-
diographic study in healthy individuals,”Circulation: Cardiovas-
cular Imaging, vol. 2, no. 1, pp. 41–46, 2009.
[11] C.G. Frazier, K. P. Alexander, L. K.Newby et al., “Associations of
gender and etiology with outcomes in heart failure with systolic
dysfunction: a pooled analysis of 5 randomized control trials,”
Journal of the American College of Cardiology, vol. 49, no. 13, pp.
1450–1458, 2007.
Journal of Aging Research 9
[12] C. D. Kimmelstiel and M. A. Konstam, “Heart failure in wom-
en,” Cardiology, vol. 86, no. 4, pp. 304–309, 1995.
[13] I. Shapira, A. Isakov, andM. Burke, “Cardiac rupture in patients
with acute myocardial infarction,” Chest, vol. 92, no. 2, pp. 219–
223, 1987.
[14] J. D. Carroll, E. P. Carroll, T. Feldman et al., “Sex-associated dif-
ferences in left ventricular function in aortic stenosis of the
elderly,” Circulation, vol. 86, no. 4, pp. 1099–1107, 1992.
[15] C. S. Hayward, R. P. Kelly, and P. Collins, “The roles of gender,
the menopause and hormone replacement on cardiovascular
function,” Cardiovascular Research, vol. 46, no. 1, pp. 28–49,
2000.
[16] M. Klein, C. Kortan, D. I. Kells, and K. J. Dorrington, “Equilib-
rium and kinetic aspects of the interaction of isolated variable
and constant domains of light chain with the Fd’ fragment of
immunoglobulin G,” Biochemistry, vol. 18, no. 8, pp. 1473–1481,
1979.
[17] P. Jousilahti, E. Vartiainen, J. Tuomilehto, and P. Puska, “Sex,
age, cardiovascular risk factors, and coronary heart disease: a
prospective follow-up study of 14 786 middle-aged men and
women in Finland,” Circulation, vol. 99, no. 9, pp. 1165–1172,
1999.
[18] S. D. Kafonek, “Postmenopausal hormone replacement therapy
and cardiovascular risk reduction. A review,” Drugs, vol. 47,
supplement, no. 2, pp. 16–24, 1994.
[19] M. J. J. de Kleijn, Y. T. van der Schouw, A. L. M. Verbeek, P. H.
M. Peeters, J.-D. Banga, and Y. van der Graaf, “Endogenous
estrogen exposure and cardiovascular mortality risk in post-
menopausal women,” American Journal of Epidemiology, vol.
155, no. 4, pp. 339–345, 2002.
[20] B. K. Jacobsen, S. Nilssen, I. Heuch, and G. Kva˚le, “Does age at
natural menopause affect mortality from ischemic heart dis-
ease?” Journal of Clinical Epidemiology, vol. 50, no. 4, pp. 475–
479, 1997.
[21] F. B. Hu, F. Grodstein, C. H. Hennekens et al., “Age at natural
menopause and risk of cardiovascular disease,” Archives of
Internal Medicine, vol. 159, no. 10, pp. 1061–1066, 1999.
[22] V. L. Jacoby, D. Grady, and G. F. Sawaya, “Oophorectomy as
a risk factor for coronary heart disease,” American Journal of
Obstetrics & Gynecology, vol. 200, no. 2, pp. 140.e1–140.e9, 2008.
[23] Y. T. van der Schouw, Y. van der Graaf, E.W. Steyerberg, M. J. C.
Eijkemans, and J. D. Banga, “Age at menopause as a risk factor
for cardiovascular mortality,”The Lancet, vol. 347, no. 9003, pp.
714–718, 1996.
[24] K. H. Lu, B. R. Hopper, T. M. Vargo, and S. S. C. Yen, “Chrono-
logical changes in sex steroid, gonadotropin and prolactin
secretion in aging female rats displaying different reproductive
states,” Biology of Reproduction, vol. 21, no. 1, pp. 193–203, 1979.
[25] S. C. Alberts, J. Altmannb, D. K. Brockman et al., “Reproductive
aging patterns in primates reveal that humans are distinct,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 110, no. 33, pp. 13440–13445, 2013.
[26] V. Ledvenyiova, D. Pancza, J. Matejikova´, M. Ferko, I. Berna-
tova, and T. Ravingerova, “Impact of age and sex on response
to ischemic preconditioning in the rat heart: differential role
of the PI3K-AKT pathway,” Canadian Journal of Physiology and
Pharmacology, vol. 91, no. 8, pp. 640–647, 2013.
[27] G. C. S. V. Tezini, C. Becari, C. Z. Zanotto, M. C. O. Salgado,
R. D. C. A. T. Passaglia, and H. C. D. Souza, “Ageing is the
main determinant of haemodynamics and autonomic cardiac
changes observed in post-menopausal female rats,” Autonomic
Neuroscience: Basic andClinical, vol. 174, no. 1-2, pp. 36–41, 2013.
[28] S. G. Campbell, P. Haynes, W. K. Snapp, K. E. Nava, and K. S.
Campbell, “Altered ventricular torsion and transmural patterns
of myocyte relaxation precede heart failure in aging F344
rats,” American Journal of Physiology—Heart and Circulatory
Physiology, vol. 305, no. 5, pp. H676–H686, 2013.
[29] T. S. Lancaster, S. J. Jefferson, J. G. Hunter et al., “Quantita-
tive proteomic analysis reveals novel mitochondrial targets of
estrogen deficiency in the aged female rat heart,” Physiological
Genomics, vol. 44, no. 20, pp. 957–969, 2012.
[30] N. M. Teno˜rio, S. Tufik, C. T. Bergamaschi et al., “Influence of
acute sleep deprivation on cardiovascular parameters in female
zucker obese and lean rats,” Obesity, vol. 21, no. 3, pp. 510–515,
2013.
[31] J. W. Simpkins, H. H. Huang, J. P. Advis, and J. Meites, “Chan-
ges in hypothalamic NE and DA turnover resulting from ster-
oid-induced LH and prolactin surges in ovariectomized rats,”
Biology of Reproduction, vol. 20, no. 3, pp. 625–632, 1979.
[32] J. P. Advis, J.W. Simpkins, H. T. Chen, and J.Meites, “Relation of
biogenic amines to onset of puberty in the female rat,” Endo-
crinology, vol. 103, no. 1, pp. 11–16, 1978.
[33] J. I. Acosta, L. Mayer, J. S. Talboom et al., “Transitional versus
surgical menopause in a rodent model: etiology of ovarian hor-
mone loss impacts memory and the acetylcholine system,”
Endocrinology, vol. 150, no. 9, pp. 4248–4259, 2009.
[34] T. A. Van Kempen, T. A. Milner, and E. M.Waters, “Accelerated
ovarian failure: a novel, chemically induced animal model of
menopause,” Brain Research, vol. 1379, pp. 176–187, 2011.
[35] C. J. Kappeler andP. B.Hoyer, “4-vinylcyclohexene diepoxide: A
model chemical for ovotoxicity,” SystemsBiology inReproductive
Medicine, vol. 58, no. 1, pp. 57–62, 2012.
[36] J. A. Parrott and M. K. Skinner, “Kit-ligand/stem cell factor
induces primordial follicle development and initiates folliculo-
genesis,” Endocrinology, vol. 140, no. 9, pp. 4262–4271, 1999.
[37] X. Jin, C.-S. Han, F.-Q. Yu, P.Wei, Z.-Y. Hu, and Y.-X. Liu, “Anti-
apoptotic action of stem cell factor on oocytes in primordial
follicles and its signal transduction,” Molecular Reproduction
and Development, vol. 70, no. 1, pp. 82–90, 2005.
[38] J. B. Frye, A. L. Lukefahr, L. E. Wright, S. L. Marion, P. B. Hoyer,
and J. L. Funk, “Modeling perimenopause in sprague-dawley
rats by chemical manipulation of the transition to ovarian
failure,” Comparative Medicine, vol. 62, no. 3, pp. 193–202, 2012.
[39] T.Kodama, J. Yoshida, T.Miwa,D.Hasegawa, andT.Masuyama,
“Collaborative work on evaluation of ovarian toxicity. 4) Effects
of fertility study of 4-vinylcyclohexene diepoxide in female rats,”
Journal of Toxicological Sciences, vol. 34, supplement 1, pp. SP59–
SP63, 2009.
[40] A. Ito, N. Mafune, and T. Kimura, “Collaborative work on eval-
uation of ovarian toxicity 4) Two- or four-week repeated dose
study of 4-vinylcyclohexene diepoxide in female rats,” The
Journal of Toxicological Sciences, vol. 34, no. 1, pp. SP53–SP58,
2009.
[41] F. S. Muhammad, A. K. Goode, N. D. Kock et al., “Effects of 4-
vinylcyclohexene diepoxide on peripubertal and adult sprague-
dawley Rats: ovarian, clinical, and pathologic outcomes,” Com-
parative Medicine, vol. 59, no. 1, pp. 46–59, 2009.
[42] R. A. Lobo, “Surgical menopause and cardiovascular risks,”
Menopause, vol. 14, no. 3, part 2, pp. 562–566, 2007.
[43] L. T. Shuster, B. S. Gostout, B. R. Grossardt, and W. A. Rocca,
“Prophylactic oophorectomy in premenopausal women and
long-term health,” Menopause International, vol. 14, no. 3, pp.
111–116, 2008.
10 Journal of Aging Research
[44] E. O¨zkaya, E. C¸akr, E. Okuyan, C. C¸akr, G. U¨stu¨n, and T.
Ku¨c¸u¨ko¨zkan, “Comparison of the effects of surgical and natural
menopause on carotid intima media thickness, osteoporosis,
and homocysteine levels,” Menopause, vol. 18, no. 1, pp. 73–76,
2011.
[45] J. H. Morrison, R. D. Brinton, P. J. Schmidt, and A. C. Gore,
“Estrogen, menopause, and the aging brain: how basic neuro-
science can inform hormone therapy in women,”The Journal of
Neuroscience, vol. 26, no. 41, pp. 10332–10348, 2006.
[46] W. A. Rocca, B. R. Grossardt, and L. T. Shuster, “Oophorectomy,
menopause, estrogen, and cognitive aging: the timing hypothe-
sis,”NeurodegenerativeDiseases, vol. 7, no. 1–3, pp. 163–166, 2010.
[47] S. D. Lee,W.-W.Kuo, Y.-J. Ho et al., “Cardiac Fas-dependent and
mitochondria-dependent apoptosis in ovariectomized rats,”
Maturitas, vol. 61, no. 3, pp. 268–277, 2008.
[48] J. P. Stice, L. Chen, S.-C. Kim et al., “17𝛽-estradiol, aging, inflam-
mation, and the stress response in the female heart,” Endocrinol-
ogy, vol. 152, no. 4, pp. 1589–1598, 2011.
[49] I. Baeza, J. Fdez-Tresguerres, C. Ariznavarreta, and M. de la
Fuente, “Effects of growth hormone, melatonin, oestrogens and
phytoestrogens on the oxidized glutathione (GSSG)/reduced
glutathione (GSH) ratio and lipid peroxidation in aged ovariec-
tomized rats,” Biogerontology, vol. 11, no. 6, pp. 687–701, 2010.
[50] B. Fabris, R. Candido, M. Bortoletto et al., “Stimulation of
cardiac apoptosis in ovariectomized hypertensive rats: potential
role of the renin-angiotensin system,” Journal of Hypertension,
vol. 29, no. 2, pp. 273–281, 2011.
[51] C.-M. Liou, A.-L. Yang, C.-H. Kuo, H. Tin, C.-Y. Huang, and
S.-D. Lee, “Effects of 17beta-estradiol on cardiac apoptosis in
ovariectomized rats,”Cell Biochemistry andFunction, vol. 28, no.
6, pp. 521–528, 2010.
[52] C. Hinojosa-Laborde, T. Craig, W. Zheng, H. Ji, J. R. Haywood,
and K. Sandberg, “Ovariectomy augments hypertension in
aging female Dahl salt-sensitive rats,”Hypertension, vol. 44, no.
4, pp. 405–409, 2004.
[53] J. F. Reckelhoff, “Sex steroids, cardiovascular disease, and
hypertension: unanswered questions and some speculations,”
Hypertension, vol. 45, no. 2, pp. 170–174, 2005.
[54] J. P. Stice, J. S. Lee, A. S. Pechenino, and A. A. Knowlton, “Estro-
gen, aging and the cardiovascular system,” Future Cardiology,
vol. 5, no. 1, pp. 93–103, 2009.
[55] O. M. Kharchilava and L. A. Valeeva, “Effects of surgical
ovariectomy on dopamine receptors of the heart and brain,”
Patologicheskaia Fiziologiia i E`ksperimental’naia Terapiia, no. 4,
pp. 21–23, 2008.
[56] M. O. Verhoeven, M. J. Van Der Mooren, T. Teerlink, R. H. M.
Verheijen, P. G. Scheffer, and P. Kenemans, “The influence
of physiological and surgical menopause on coronary heart
disease risk markers,”Menopause, vol. 16, no. 1, pp. 37–49, 2009.
[57] C. M. Wong, X. Yao, C. L. Au et al., “Raloxifene prevents endo-
thelial dysfunction in aging ovariectomized female rats,”Vascu-
lar Pharmacology, vol. 44, no. 5, pp. 290–298, 2006.
[58] G. Olivetti, G. Giordano, D. Corradi et al., “Gender differences
and aging: effects on the human heart,” Journal of the American
College of Cardiology, vol. 26, no. 4, pp. 1068–1079, 1995.
[59] A. L. Danneberg, D. Levy, and R. J. Garrison, “Impact of age on
echocardiographic left ventricular mass in a healthy population
(the Framingham Study),” American Journal of Cardiology, vol.
64, no. 16, pp. 1066–1068, 1989.
[60] A. S. Go, “The epidemiology of atrial fibrillation in elderly per-
sons: the tip of the iceberg,” The American Journal of Geriatric
Cardiology, vol. 14, no. 2, pp. 56–61, 2005.
[61] M. O. Boluyt, K. Converso, H. S. Hwang, A. Mikkor, and M.
W. Russell, “Echocardiographic assessment of age-associated
changes in systolic and diastolic function of the female F344 rat
heart,” Journal of Applied Physiology, vol. 96, no. 2, pp. 822–828,
2004.
[62] M. O. Boluyt, S. T. Devor, J. A. Opiteck, and T. P. White,
“Regional variation in cardiac myosin isoforms of female F344
rats during aging,” Journals of Gerontology Series A: Biological
Sciences andMedical Sciences, vol. 54, no. 8, pp. B313–B317, 1999.
[63] M.O. Boluyt, J. A.Opiteck, K. A. Esser, andT. P.White, “Cardiac
adaptations to aortic constriction in adult and aged rats,” The
American Journal of Physiology—Heart and Circulatory Physiol-
ogy, vol. 257, no. 2, pp. H643–H648, 1989.
[64] S. Miyata, W. Minobe, M. R. Bristow, and L. A. Leinwand,
“Myosin heavy chain isoform expression in the failing and
nonfailing human heart,”Circulation Research, vol. 86, no. 4, pp.
386–390, 2000.
[65] J. Fannin, K. M. Rice, S. Thulluri et al., “Age-associated alter-
ations of cardiac structure and function in the female F344xBN
rat heart,” AGE, vol. 36, article 9684, 2014.
[66] D. R. Meldrum, M. Wang, B. M. Tsai et al., “Intracellular sig-
naling mechanisms of sex hormones in acute myocardial
inflammation and injury,” Frontiers in Bioscience, vol. 10, no. 2,
pp. 1835–1867, 2005.
[67] A. K. Gupta, A. Maheshwari, D. D. Tresch, and R. K. Thakur,
“Cardiac arrhythmias in the elderly,” Cardiac Electrophysiology
Review, vol. 6, no. 1-2, pp. 120–128, 2002.
[68] S. Rossi, S. Baruffi, A. Bertuzzi et al., “Ventricular activation is
impaired in aged rat hearts,”TheAmerican Journal of Physiology:
Heart and Circulatory Physiology, vol. 295, no. 6, pp. H2336–
H2347, 2008.
[69] S. Xing, S.-W. Tsaih, R. Yuan et al., “Genetic influence on elec-
trocardiogram time intervals and heart rate in aging mice,”
American Journal of Physiology: Heart and Circulatory Physiol-
ogy, vol. 296, no. 6, pp. H1907–H1913, 2009.
[70] V. J. D. da Silva, E. F. Neto, H. C. Salgado, and R. F. Ju´nior,
“Chronic converting enzyme inhibition normalizes QT interval
in aging rats,” Brazilian Journal of Medical and Biological
Research, vol. 35, no. 9, pp. 1025–1031, 2002.
[71] U. Molander, D. K. Dey, V. Sundh, and B. Steen, “ECG abnor-
malities in the elderly: prevalence, time and generation trends
and associationwithmortality,”AgingClinical andExperimental
Research, vol. 15, no. 6, pp. 488–493, 2003.
[72] A. F. James, S. C.M. Choisy, and J. C. Hancox, “Recent advances
in understanding sex differences in cardiac repolarization,”
Progress in Biophysics and Molecular Biology, vol. 94, no. 3, pp.
265–319, 2007.
[73] P. W. Macfarlane, S. C. McLaughlin, B. Devine, and T. F. Yang,
“Effects of age, sex, and race on ECG interval measurements,”
Journal of Electrocardiology, vol. 27, pp. 14–19, 1994.
[74] T. Taneja, B. W. Mahnert, R. O. D. Passman, J. Goldberger, and
A. Kadish, “Effects of sex and age on electrocardiographic and
cardiac electrophysiological properties in adults,” PACE-Pacing
and Clinical Electrophysiology, vol. 24, no. 1, pp. 16–21, 2001.
[75] D. Levy, J. J. Bailey, R. J. Garrison et al., “Electrocardiographic
changes with advancing age. A cross-sectional study of the
association of age with QRS axis, duration and voltage,” Journal
of Electrocardiology, vol. 20, pp. 44–47, 1987.
[76] P. Rautaharju, S. H. Zhou, S. Wong et al., “Sex differences in
the evolution of the electrocardiographic QT interval with age,”
Canadian Journal of Cardiology, vol. 8, no. 7, pp. 690–695, 1992.
Journal of Aging Research 11
[77] R. J. Pocchiari, R. L. Hamlin, and S. A. McCune, “Electrocar-
diographic findings in rats with cardiomyopathy,”TheAmerican
Journal of Veterinary Research, vol. 54, no. 4, pp. 607–611, 1993.
[78] I. Netuka, O. Sza´rszoi, J. Maly´ et al., “Late effect of early hypoxic
disturbance in the rat heart: gender differences,” Physiological
Research, vol. 59, no. 1, pp. 127–131, 2010.
[79] J. A. Wasserstrom, S. Kapur, S. Jones et al., “Characteristics
of intracellular Ca2+ cycling in intact rat heart: a comparison
of sex differences,” American Journal of Physiology-Heart and
Circulatory Physiology, vol. 295, no. 5, pp. H1895–H1904, 2008.
[80] K. L. Philp, M. Hussain, N. F. Byrne, M. J. Diver, G. Hart, and S.
J. Coker, “Greater antiarrhythmic activity of acute 17𝛽-estradiol
in female than male anaesthetized rats: correlation with Ca2+
channel blockade,” British Journal of Pharmacology, vol. 149, no.
3, pp. 233–242, 2006.
[81] C. Jiang, P. A. Poole-Wilson, P. M. Sarrel, S. Mochizuki, P.
Collins, and K. T. MacLeod, “Effect of 17𝛽-oestradiol on con-
traction, Ca2+ current and intracellular free Ca2+ in guinea-pig
isolated cardiac myocytes,” British Journal of Pharmacology, vol.
106, no. 3, pp. 739–745, 1992.
[82] ICH, “Guidance for industry: S7B nonclinical evaluation of the
potential for delayed ventricular repolarization (QT interval
prolongation) by human pharmaceuticals,” in Proceedings of
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for HumanUse
(ICH ’05), U.S. Department of Health and Human Services,
Food and Drug Administration, Center for Drug Evaluation
and Research (CDER), and Center for Biologics Evaluation and
Research (CBER), Eds., pp. 1–10, Rockville, Md, USA, 2005.
[83] L. K. Bhatt, K. Nandakumar, and S. L. Bodhankar, “Experimen-
tal animal models to induce cardiac arrhythmias,” Indian Jour-
nal of Pharmacology, vol. 37, no. 6, pp. 348–357, 2005.
[84] W. E. Louch,M.K. Stokke, I. Sjaastad,G. Christensen, andO.M.
Sejersted, “No rest for the weary: diastolic calcium homeostasis
in the normal and failing myocardium,” Physiology, vol. 27, no.
5, pp. 308–323, 2012.
[85] S. J. Shipsey, S. M. Bryant, and G. Hart, “Effects of hypertrophy
on regional action potential characteristics in the rat left
ventricle: a cellular basis for T-wave inversion?”Circulation, vol.
96, no. 6, pp. 2061–2068, 1997.
[86] Z. Tatarkova´, S. Kuka, P. Racˇay et al., “Effects of aging on activ-
ities of mitochondrial electron transport chain complexes and
oxidative damage in rat heart,” Physiological Research, vol. 60,
no. 2, pp. 281–289, 2011.
[87] H. Huang and K. G. Manton, “The role of oxidative damage in
mitochondria during aging: a review,” Frontiers in Bioscience,
vol. 9, pp. 1100–1117, 2004.
[88] S. Asano, K.M. Rice, S. Kakarla et al., “Aging influencesmultiple
indices of oxidative stress in the heart of the Fischer 344/NNia x
Brown Norway/BiNia rat,” Redox Report, vol. 12, no. 4, pp. 167–
180, 2007.
[89] R. Kayali, U. C¸akatay,H.Uzun, andH.Genc¸, “Gender difference
as regards myocardial protein oxidation in aged rats: male rats
have increased oxidative protein damage,” Biogerontology, vol.
8, no. 6, pp. 653–661, 2007.
[90] B. Colom, J. Oliver, P. Roca, and F. J. Garcia-Palmer, “Caloric





production and oxidative damage,” Cardiovascular
Research, vol. 74, no. 3, pp. 456–465, 2007.
[91] C. Borra´s, J. Sastre, D. Garc´ıa-Sala, A. Lloret, F. V. Pallardo´, and
J. Vin˜a, “Mitochondria from females exhibit higher antioxidant
gene expression and lower oxidative damage than males,” Free
Radical Biology & Medicine, vol. 34, no. 5, pp. 546–552, 2003.
[92] Y. M. Jang, S. Kendaiah, B. Drew et al., “Doxorubicin treatment
in vivo activates caspase-12 mediated cardiac apoptosis in both
male and female rats,” FEBS Letters, vol. 577, no. 3, pp. 483–490,
2004.
[93] M. Strniskova, M. Barancik, and T. Ravingerova, “Mitogen-
activated protein kinases and their role in regulation of cellular
processes,” General Physiology and Biophysics, vol. 21, no. 3, pp.
231–255, 2002.
[94] T. P. Garrington and G. L. Johnson, “Organization and regu-
lation of mitogen-activated protein kinase signaling pathways,”
Current Opinion in Cell Biology, vol. 11, no. 2, pp. 211–218, 1999.
[95] S. L. House, B. E. House, B. Glascock et al., “Fibroblast growth
factor 2 mediates isoproterenol-induced cardiac hypertrophy
through activation of the extracellular regulated kinase,”Molec-
ular and Cellular Pharmacology, vol. 2, no. 4, pp. 143–154, 2010.
[96] L. E. Lemke, L. J. Bloem, R. Fouts, M. Esterman, G. Sandusky,
and C. J. Vlahos, “Decreased p38 MAPK activity in end-stage
failing human myocardium: p38 MAPK 𝛼 is the predominant
isoform expressed in human heart,” Journal of Molecular and
Cellular Cardiology, vol. 33, no. 8, pp. 1527–1540, 2001.
[97] C. Communal, W. S. Colucci, A. Remondino et al., “Reciprocal
modulation of mitogen-activated protein kinases and mitogen-
activated protein kinase phosphatase 1 and 2 in failing human
myocardium,” Journal of Cardiac Failure, vol. 8, no. 2, pp. 86–92,
2002.
[98] J. N. Peart, E. R. Gross, J. P. Headrick, and G. J. Gross, “Impaired
p38 MAPK/HSP27 signaling underlies aging-related failure in
opioid-mediated cardioprotection,” Journal of Molecular and
Cellular Cardiology, vol. 42, no. 5, pp. 972–980, 2007.
[99] A. A. Knowlton, P. Brecher, andC. S. Apstein, “Rapid expression
of heat shock protein in the rabbit after brief cardiac ischemia,”
Journal of Clinical Investigation, vol. 87, no. 1, pp. 139–147, 1991.
[100] S. Storti, S. Vittorini, M. R. Iascone et al., “Analysis of the
variation in the hsp70-1 and hsp90alpha mRNA expression in
human myocardial tissue that has undergone surgical stress,”
Cell Stress Chaperones, vol. 8, no. 1, pp. 18–25, 2003.
[101] I. J. Benjamin andD. R.McMillan, “Stress (heat shock) proteins:
molecular chaperones in cardiovascular biology and disease,”
Circulation Research, vol. 83, no. 2, pp. 117–132, 1998.
[102] M. Tatar, A. A. Khazaeli, and J. W. Curtsinger, “Chaperoning
extended life,” Nature, vol. 390, no. 6655, p. 30, 1997.
[103] W. E. Balch, R. I. Morimoto, A. Dillin, and J.W. Kelly, “Adapting
proteostasis for disease intervention,” Science, vol. 319, no. 5865,
pp. 916–919, 2008.
[104] W. R. Swindell, M. M. Masternak, J. J. Kopchick, C. A. Conover,
A. Bartke, and R. A.Miller, “Endocrine regulation of heat shock
protein mRNA levels in long-lived dwarf mice,”Mechanisms of
Ageing and Development, vol. 130, no. 6, pp. 393–400, 2009.
[105] S. D. Westerheide and R. I. Morimoto, “Heat shock response
modulators as therapeutic tools for diseases of protein confor-
mation,”The Journal of Biological Chemistry, vol. 280, no. 39, pp.
33097–33100, 2005.
[106] J. W. Starnes, A. M. Choilawala, R. P. Taylor, M. J. Nelson, and
M. D. Delp, “Myocardial heat shock protein 70 expression in
young and old rats after identical exercise programs,” Journals of
Gerontology—Series A Biological Sciences and Medical Sciences,
vol. 60, no. 8, pp. 963–969, 2005.
[107] J. M. Lawler, H.-B. Kwak, J.-H. Kim, and M.-H. Suk, “Exercise
training inducibility of MnSOD protein expression and activity
12 Journal of Aging Research
is retained while reducing prooxidant signaling in the heart
of senescent rats,” American Journal of Physiology: Regulatory
Integrative and Comparative Physiology, vol. 296, no. 5, pp.
R1496–R1502, 2009.
[108] K. C. Kregel, P. L. Moseley, R. Skidmore, J. A. Gutierrez, and
V. Guerriero Jr., “HSP70 accumulation in tissues of heat-
stressed rats is blunted with advancing age,” Journal of Applied
Physiology, vol. 79, no. 5, pp. 1673–1678, 1995.
[109] B. Chandrasekar and G. L. Freeman, “Induction of nuclear
factor 𝜅Band activation protein 1 in postischemicmyocardium,”
FEBS Letters, vol. 401, no. 1, pp. 30–34, 1997.
[110] C. Li, W. Browder, and R. L. Kao, “Early activation of tran-
scription factor NF-kappaB during ischemia in perfused rat
heart,” American Journal of Physiology-Heart and Circulatory
Physiology, vol. 276, no. 2, pp. H543–H552, 1999.
[111] S. C. Y. Wong, M. Fukuchi, P. Melnyk, I. Rodger, and A.
Giaid, “Induction of cyclooxygenase-2 and activation of nuclear
factor-𝜅B in myocardium of patients with congestive heart
failure,” Circulation, vol. 98, no. 2, pp. 100–103, 1998.
[112] S. Frantz, D. Fraccarollo, H.Wagner et al., “Sustained activation
of nuclear factor kappa B and activator protein 1 in chronic
heart failure,” Cardiovascular Research, vol. 57, no. 3, pp. 749–
756, 2003.
[113] M. J. May and S. Ghosh, “Signal transduction through NF-𝜅B,”
Immunology Today, vol. 19, no. 2, pp. 80–88, 1998.
[114] G. Bonizzi and M. Karin, “The two NF-𝜅B activation pathways
and their role in innate and adaptive immunity,” Trends in
Immunology, vol. 25, no. 6, pp. 280–288, 2004.
[115] M. Wang, P. Crisostomo, G. M. Wairiuko, and D. R. Meldrum,
“Estrogen receptor-𝛼 mediates acute myocardial protection in
females,” American Journal of Physiology: Heart and Circulatory
Physiology, vol. 290, no. 6, pp. H2204–H2209, 2006.
[116] M. Wang, B. M. Tsai, K. M. Reiger, J. W. Brown, and D. R.
Meldrum, “17-𝛽-Estradiol decreases p38 MAPK-mediated
myocardial inflammation and dysfunction following acute
ischemia,” Journal of Molecular and Cellular Cardiology, vol. 40,
no. 2, pp. 205–212, 2006.
[117] W. Cheng, L. Chen, S. Yang et al., “Puerarin suppresses pro-
liferation of endometriotic stromal cells partly via the MAPK
signaling pathway induced by 17ss-estradiol-BSA,” PLoS ONE,
vol. 7, no. 9, Article ID e45529, 2012.
[118] S. Nuedling, S. Kahlert, K. Loebbert, R. Meyer, H. Vetter, and
C. Grohe´, “Differential effects of 17𝛽-estradiol on mitogen-
activated protein kinase pathways in rat cardiomyocytes,” FEBS
Letters, vol. 454, no. 3, pp. 271–276, 1999.
[119] C. S. Watson, A. M. Norfleet, T. C. Pappas, and B. Gametchu,
“Rapid actions of estrogens in GH3/B6 pituitary tumor cells via
a plasma membrane version of estrogen receptor-𝛼,” Steroids,
vol. 64, no. 1-2, pp. 5–13, 1999.
[120] M. van Eickels, C. Grohe´, J. P. M. Cleutjens, B. J. Janssen, H. J.
J. Wellens, and P. A. Doevendans, “17𝛽-estradiol attenuates the
development of pressure-overload hypertrophy,” Circulation,
vol. 104, no. 12, pp. 1419–1423, 2001.
[121] M. R. Voss, J. N. Stallone, M. Li, R. N. M. Cornelussen, P.
Knuefermann, and A. A. Knowlton, “Gender differences in the
expression of heat shock proteins: the effect of estrogen,” Amer-
ican Journal of Physiology-Heart and Circulatory Physiology, vol.
285, no. 2, pp. H687–H692, 2003.
[122] A. A. Knowlton and L. Sun, “Heat-shock factor-1, steroid hor-
mones, and regulation of heat-shock protein expression in the
heart,” American Journal of Physiology: Heart and Circulatory
Physiology, vol. 280, no. 1, pp. H455–H464, 2001.
[123] K. Rayner, J. Sun, Y.-X. Chen et al., “Heat shock protein
27 protects against atherogenesis via an estrogen-dependent
mechanism: role of selective estrogen receptor beta modula-
tion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29,
no. 11, pp. 1751–1756, 2009.
[124] A. S.Al-Madhoun,Y.-X.Chen, L.Haidari et al., “The interaction
and cellular localization of HSP27 and ER𝛽 are modulated
by 17𝛽-estradiol and HSP27 phosphorylation,” Molecular and
Cellular Endocrinology, vol. 270, no. 1-2, pp. 33–42, 2007.
[125] C. Borras, J. Gambini, M. C. Go´mez-Cabrera et al., “17beta-
oestradiol up-regulates longevity-related, antioxidant enzyme
expression via the ERK1 and ERK2[MAPK]/NFkappaB cas-
cade,” Aging Cell, vol. 4, no. 3, pp. 113–118, 2005.
[126] G. W. Dorn II, “Apoptotic and non-apoptotic programmed car-
diomyocyte death in ventricular remodelling,” Cardiovascular
Research, vol. 81, no. 3, pp. 465–473, 2009.
[127] R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson,
“Cell death,”The New England Journal of Medicine, vol. 361, no.
16, pp. 1570–1583, 2009.
[128] G. Olivetti, R. Abbi, F. Quaini et al., “Apoptosis in the failing
human heart,” The New England Journal of Medicine, vol. 336,
no. 16, pp. 1131–1141, 1997.
[129] S. Hein, E. Arnon, S. Kostin et al., “Progression from compen-
sated hypertrophy to failure in the pressure-overloaded human:
heart structural deterioration and compensatory mechanisms,”
Circulation, vol. 107, no. 7, pp. 984–991, 2003.
[130] M.M. Gallogly, M. D. Shelton, S. Qanungo et al., “Glutaredoxin
regulates apoptosis in cardiomyocytes via NF𝜅b targets Bcl-2
and Bcl-xl: implications for cardiac aging,” Antioxidants and
Redox Signaling, vol. 12, no. 12, pp. 1339–1353, 2010.
[131] S. K. Kakarla, J. C. Fannin, S. Keshavarzian et al., “Chronic
acetaminophen attenuates age-associated increases in cardiac
ROS and apoptosis in the Fischer Brown Norway rat,” Basic
Research in Cardiology, vol. 105, no. 4, pp. 535–544, 2010.
[132] V. Ljubicic, K. J. Menzies, and D. A. Hood, “Mitochondrial
dysfunction is associated with a pro-apoptotic cellular environ-
ment in senescent cardiac muscle,” Mechanisms of Ageing and
Development, vol. 131, no. 2, pp. 79–88, 2010.
[133] S. K. Kakarla, K. M. Rice, A. Katta et al., “Possible molecular
mechanisms underlying age-related cardiomyocyte apoptosis
in the F344XBN rat heart,” The Journals of Gerontology A:
Biological Sciences and Medical Sciences, vol. 65, no. 2, pp. 147–
155, 2010.
[134] Z. Mallat, P. Fornes, R. Costagliola et al., “Age and gender
effects on cardiomyocyte apoptosis in the normal human heart,”
Journals of Gerontology Series A: Biological Sciences andMedical
Sciences, vol. 56, no. 11, pp. M719–M723, 2001.
[135] G. G. L. Biondi-Zoccai, A. Baldi, L. M. Biasucci, and A. Abbate,
“Female gender, myocardial remodeling and cardiac failure: are
women protected from increased myocardiocyte apoptosis?”
Italian Heart Journal, vol. 5, no. 7, pp. 498–504, 2004.
[136] M. Challah, S. Nadaud, M. Philippe et al., “Circulating and
cellular markers of endothelial dysfunction with aging in rats,”
American Journal of Physiology, vol. 273, no. 4, part 2, pp.H1941–
H1948, 1997.
[137] S. S. Najjar, A. Scuteri, and E. G. Lakatta, “Arterial aging: is it
an immutable cardiovascular risk factor?”Hypertension, vol. 46,
no. 3, pp. 454–462, 2005.
[138] D. H. O’Leary, J. F. Polak, R. A. Kronmal, T. A. Manolio, G. L.
Burke, and S. K. Wolfson Jr., “Carotid-artery intima and media
thickness as a risk factor for myocardial infarction and stroke
Journal of Aging Research 13
in older adults,”The New England Journal of Medicine, vol. 340,
no. 1, pp. 14–22, 1999.
[139] A. U. Ferrari, A. Radaelli, andM. Centola, “Aging and the cardi-
ovascular system,” Journal of Applied Physiology, vol. 95, no. 6,
pp. 2591–2597, 2003.
[140] S. J. Miller, W. C. Watson, K. A. Kerr et al., “Development of
progressive aortic vasculopathy in a rat model of aging,”
The American Journal of Physiology—Heart and Circulatory
Physiology, vol. 293, no. 5, pp. H2634–H2643, 2007.
[141] W. Zhang, X. Zhang, and Y. Zhang, “Evaluation of thoracic
aortic anatomy and function with transesophageal echocardio-
graphy,” Zhonghua Yi Xue Za Zhi, vol. 78, no. 9, pp. 666–669,
1998.
[142] J. J. van der Heijden-Spek, J. A. Staessen, R. H. Fagard, A. P.
Hoeks, H. A. Struijker Boudier, and L. M. Van Bortel, “Effect
of age on brachial artery wall properties differs from the aorta
and is gender dependent: a population study,”Hypertension, vol.
35, no. 2, pp. 637–642, 2000.
[143] P. Albaladejo, P. Laurent, B. Pannier, A. Achimastos, M. Safar,
and A. Benetos, “Influence of sex on the relation between heart
rate and aortic stiffness,” Journal of Hypertension, vol. 21, no. 3,
pp. 555–562, 2003.
[144] H. Qiu, B. Tian, R. G. Resuello et al., “Sex-specific regulation
of gene expression in the aging monkey aorta,” Physiological
Genomics, vol. 29, no. 2, pp. 169–180, 2007.
[145] G.Gennaro, C.Me´nard, E.Giasson et al., “Role of p44/p42MAP
kinase in the age-dependent increase in vascular smoothmuscle
cell proliferation and neointimal formation,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 204–210,
2003.
[146] E. Porreca, R. Ciccarelli, C. Di Febbo, and F. Cuccurullo, “Pro-
tein kinase C pathway and proliferative responses of aged and
young rat vascular smooth muscle cells,” Atherosclerosis, vol.
104, no. 1-2, pp. 137–145, 1993.
[147] R. J. Hariri, D. R. Alonso, D. P. Hajjar, D. Coletti, and M. E.
Weksler, “Aging and arteriosclerosis. I. Development of myoin-
timal hyperplasia after endothelial injury,” Journal of Experi-
mental Medicine, vol. 164, no. 4, pp. 1171–1178, 1986.
[148] V. Sagach, A. Bondarenko, O. Bazilyuk, and A. Kotsuruba,
“Endothelial dysfunction: possible mechanisms and ways of
correction,” Experimental & Clinical Cardiology, vol. 11, no. 2,
pp. 107–110, 2006.
[149] T. Hayashi and A. Iguchi, “Possibility of the regression of athe-
rosclerosis through the prevention of endothelial senescence
by the regulation of nitric oxide and free radical scavengers,”
Geriatrics and Gerontology International, vol. 10, no. 2, pp. 115–
130, 2010.
[150] D. M. Dudzinski and T. Michel, “Life history of eNOS: partners
and pathways,” Cardiovascular Research, vol. 75, no. 2, pp. 247–
260, 2007.
[151] F. M. Ho, W. W. Lin, B. C. Chen et al., “High glucose-induced
apoptosis in human vascular endothelial cells is mediated
through NF-𝜅B and c-Jun NH2-terminal kinase pathway and
prevented by PI3K/Akt/eNOS pathway,” Cellular Signalling, vol.
18, no. 3, pp. 391–399, 2006.
[152] Y. C. Boo and H. Jo, “Flow-dependent regulation of endothelial
nitric oxide synthase: role of protein kinases,” The American
Journal of Physiology—Cell Physiology, vol. 285, no. 3, pp. C499–
C508, 2003.
[153] Y. Dohi, M. Kojima, K. Sato, and T. F. Luscher, “Age-related
changes in vascular smooth muscle and endothelium,” Drugs
and Aging, vol. 7, no. 4, pp. 278–291, 1995.
[154] J. Hoffmann, J. Haendeler, A. Aicher et al., “Aging enhances
the sensitivity of endothelial cells toward apoptotic stimuli:
important role of nitric oxide,” Circulation Research, vol. 89, no.
8, pp. 709–715, 2001.
[155] R. P. Brandes, I. Fleming, and R. Busse, “Endothelial aging,”
Cardiovascular Research, vol. 66, no. 2, pp. 286–294, 2005.
[156] J. H. Kim, L. J. Bugaj, J. O. Young et al., “Arginase inhibition
restores NOS coupling and reverses endothelial dysfunction
and vascular stiffness in old rats,” Journal of Applied Physiology,
vol. 107, no. 4, pp. 1249–1257, 2009.
[157] S. Chakrabarti, O. Lekontseva, A. Peters, and S. T. Davidge,
“17𝛽-Estradiol induces protein S-nitrosylation in the endothe-
lium,”Cardiovascular Research, vol. 85, no. 4, pp. 796–805, 2010.
[158] J. P. Stice, J. P. Eiserich, and A. A. Knowlton, “Role of aging
versus the loss of estrogens in the reduction in vascular function
in female rats,” Endocrinology, vol. 150, no. 1, pp. 212–219, 2009.
[159] J. Widder, T. Pelzer, C. von Poser-Klein et al., “Improvement
of endothelial dysfunction by selective estrogen receptor-𝛼
stimulation in ovariectomized SHR,” Hypertension, vol. 42, no.
5, pp. 991–996, 2003.
[160] P. Angerer, S. Sto¨rk, W. Kothny, P. Schmitt, and C. Von
Schacky, “Effect of oral postmenopausal hormone replacement
on progression of atherosclerosis: a randomized, controlled
trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21,
no. 2, pp. 262–268, 2001.
[161] S. Ling, A. Dai, R. J. Dilley et al., “Endogenous estrogen defi-
ciency reduces proliferation and enhances apoptosis-related
death in vascular smooth muscle cells: insights from the
aromatase-knockout mouse,” Circulation, vol. 109, no. 4, pp.
537–543, 2004.
[162] E. Espinosa, E. Espinosa, B. S. Oemar, B. S. Oemar, T. F. Luscher,
and T. F. Lu¨scher, “17𝛽-estradiol and smooth muscle cell
proliferation in aortic cells ofmale and female rats,”Biochemical
and Biophysical Research Communications, vol. 221, no. 1, pp. 8–
14, 1996.
[163] A. Suzuki, K. Mizuno, Y. Ino et al., “Effects of 17𝛽-estradiol
and progesterone on growth-factor-induced proliferation and
migration in human female aortic smoothmuscle cells in vitro,”
Cardiovascular Research, vol. 32, no. 3, pp. 516–523, 1996.
[164] W.-S. Lee, J. A. Harder, M. Yoshizumi, M.-E. Lee, and E. Haber,
“Progesterone inhibits arterial smooth muscle cell prolifera-
tion,” Nature Medicine, vol. 3, no. 9, pp. 1005–1008, 1997.
[165] C. Bolego, A. Cignarella, V. Zancan, C. Pinna, R. Zanardo, and
L. Puglisi, “Diabetes abolishes the vascular protective effects of
estrogen in female rats,” Life Sciences, vol. 64, no. 9, pp. 741–749,
1999.
[166] Q.-W. Chen, L. Edvinsson, and C.-B. Xu, “Role of ERK/MAPK
in endothelin receptor signaling in human aortic smooth
muscle cells,” BMC Cell Biology, vol. 10, article 52, 2009.
[167] T. Zou, W. Yang, Z. Hou, and J. Yang, “Homocysteine enhances
cell proliferation in vascular smooth muscle cells: Role of p38
MAPK and p47phox,” Acta Biochimica et Biophysica Sinica, vol.
42, no. 12, pp. 908–915, 2010.
[168] I. Bhattacharya, M. Damjanovic´, A. Perez Dominguez, and E.
Haas, “Inhibition of activated ERK1/2 and JNKs improves vas-
cular function in mouse aortae in the absence of nitric oxide,”
European Journal of Pharmacology, vol. 658, no. 1, pp. 22–27,
2011.
[169] K. M. Rice, E. M. Walker, S. K. Kakarla et al., “Fluprostenol-
induced MAPK signaling is independent of aging in Fischer
344/NNiaHSd x Brown Norway/BiNia rat aorta,” Annals of
Clinical and Laboratory Science, vol. 40, no. 1, pp. 26–31, 2010.
14 Journal of Aging Research
[170] K. M. Rice, R. S. Kinnard, R. Harris, G. L. Wright, and E. R.
Blough, “Effects of aging on pressure-inducedMAPK activation
in the rat aorta,” Pflu¨gers Archiv, vol. 450, no. 3, pp. 192–199,
2005.
[171] A. J. Lusis, “Atherosclerosis,”Nature, vol. 407, no. 6801, pp. 233–
241, 2000.
[172] N. K. Fukagawa, M. Li, C. R. Timblin, and B. T. Mossman,
“Modulation of cell injury and survival by high glucose and
advancing age,” Free Radical Biology & Medicine, vol. 31, no. 12,
pp. 1560–1569, 2001.
[173] R. V. Sharma,M. V. Gurjar, and R. C. Bhalla, “Selected contribu-
tion: estrogen receptor-alpha gene transfer inhibits proliferation
and NF-kappaB activation in VSM cells from female rats,”
Journal of Applied Physiology, vol. 91, no. 5, pp. 2400–2389, 2001.
[174] D. Xing, S. Nozell, Y. F. Chen, F. Hage, and S. Oparil, “Estro-
gen and mechanisms of vascular protection,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 289–295,
2009.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
